Brief: Monte Rosa Therapeutics Announces Global License Pact With Novartis To Advance T And B Cell-Modulating Vav1-Directed Molecular Glue Degraders
28/10/2024 11:00
Oct 28 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS: GLOBAL LICENSE PACT WITH NOVARTIS
TO
ADVANCE T AND B CELL-MODULATING VAV1-DIRECTED MOLECULAR GLUE
DEGRADERS
* MONTE ROSA THERAPEUTICS: CO TO GET UP-FRONT PAYMENT OF
$150
MILLION & ELIGIBLE TO GET MILESTONE PAYMENTS
* MONTE ROSA THERAPEUTICS: NOVARTIS TO OBTAIN WORLDWIDE
RIGHTS TO
DEVELOP, MANUFACTURE & COMMERCIALIZE MRT-6160 AND OTHER VAV1
MGDS
((Reuters.Briefs@thomsonreuters.com))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million